MA29803B1 - Formulation retard pour le pralnacasan - Google Patents
Formulation retard pour le pralnacasanInfo
- Publication number
- MA29803B1 MA29803B1 MA30779A MA30779A MA29803B1 MA 29803 B1 MA29803 B1 MA 29803B1 MA 30779 A MA30779 A MA 30779A MA 30779 A MA30779 A MA 30779A MA 29803 B1 MA29803 B1 MA 29803B1
- Authority
- MA
- Morocco
- Prior art keywords
- pralnacasan
- type
- delay formulation
- releases
- layer
- Prior art date
Links
- CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 title abstract 3
- 229950000362 pralnacasan Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'INVENTION CONCERNE DES COMPRIMÉS À EFFET RETARD COMPRENANT AU MOINS DEUX COUCHES, CES COMPRIMÉS ÉTANT CARACTÉRISÉS EN CE QU'AU MOINS UNE COUCHE LIBÈRE RAPIDEMENT LE MÉDICAMENT 1S, 9S (RS, 3S) N-(2-ÉTHOXY-5-OXO-TÉTRAFURANE-3-YL)-6,10-DIOXO-9-(ISOQUINOLÉINE-1-OYL-AMINO)-1, 2, 3, 4, 7, 8, 9, 10-OCTAHYDRO-6-H-PYRIDAZINO [1, 2-A] [1, 2] DIAZÉPINE-1-CARBOXAMIDE ET/OU SES SELS OU DÉRIVÉS ET/OU LES ACIDES LIBRES DE CEUX-CI ET EN CE QU'AU MOINS UNE COUCHE LIBÈRE LE MÉDICAMENT 1S, 9S (RS, 3S) N-(2-ÉTHOXY-5-OXO-TÉTRAFURANE-3-YL)-6,10-DIOXO-9-(ISOQUINOLÉINE-1-OYL-AMINO)-1, 2, 3, 4, 7, 8, 9, 10-OCTAHYDRO-6-H-PYRIDAZINO [1, 2-A] [1, 2] DIAZÉPINE-1-CARBOXAMIDE ET/OU SES SELS OU DÉRIVÉS ET/OU LES ACIDES LIBRES DE CEUX-CI DE FAÇON DIFFÉRÉE POUR TRAITER DES MALADIES AUTO-IMMUNES, LE DIABÈTE DE TYPE I ET DE TYPE II, LA POLYARTHRITE RHUMATOÏDE, L'OSTÉOARTHRITE ET/OU LE PSORIASIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048293A DE102005048293A1 (de) | 2005-10-08 | 2005-10-08 | Retardformulierung für Pralnacasan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29803B1 true MA29803B1 (fr) | 2008-09-01 |
Family
ID=37764039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30779A MA29803B1 (fr) | 2005-10-08 | 2008-03-24 | Formulation retard pour le pralnacasan |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8231904B2 (fr) |
| EP (1) | EP1937221B1 (fr) |
| JP (1) | JP2009511441A (fr) |
| KR (1) | KR101362679B1 (fr) |
| CN (1) | CN101277683B (fr) |
| AT (1) | ATE422354T1 (fr) |
| AU (1) | AU2006301573B2 (fr) |
| BR (1) | BRPI0617184A2 (fr) |
| CA (1) | CA2624838C (fr) |
| CY (1) | CY1109131T1 (fr) |
| DE (2) | DE102005048293A1 (fr) |
| DK (1) | DK1937221T3 (fr) |
| ES (1) | ES2322202T3 (fr) |
| HR (1) | HRP20090254T1 (fr) |
| IL (1) | IL190511A (fr) |
| MA (1) | MA29803B1 (fr) |
| ME (1) | ME01735B (fr) |
| MY (1) | MY146552A (fr) |
| NO (1) | NO339360B1 (fr) |
| NZ (1) | NZ567268A (fr) |
| PL (1) | PL1937221T3 (fr) |
| PT (1) | PT1937221E (fr) |
| RS (1) | RS50777B (fr) |
| RU (1) | RU2419419C2 (fr) |
| SI (1) | SI1937221T1 (fr) |
| WO (1) | WO2007042160A1 (fr) |
| ZA (1) | ZA200802031B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2596787C2 (ru) * | 2010-07-09 | 2016-09-10 | БиЭйчВи ФАРМА, ИНК. | Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина |
| AU2011288413B2 (en) * | 2010-08-13 | 2014-05-22 | Mundipharma Pty Limited | Use of binders for manufacturing storage stable formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| CN1524526A (zh) * | 2003-03-02 | 2004-09-01 | 颖 王 | 尼群地平双层缓释制剂 |
| US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| CN1579401A (zh) * | 2003-08-11 | 2005-02-16 | 李亦武 | 一种止咳平喘药物新剂型及制备方法 |
| US7611728B2 (en) * | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| WO2005048979A2 (fr) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Composition pharmaceutique avec capsule pour microtablettes multiples |
| WO2005051350A2 (fr) * | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Comprime dispersible dans l'eau |
-
2005
- 2005-10-08 DE DE102005048293A patent/DE102005048293A1/de not_active Ceased
-
2006
- 2006-09-29 PT PT06805947T patent/PT1937221E/pt unknown
- 2006-09-29 NZ NZ567268A patent/NZ567268A/en not_active IP Right Cessation
- 2006-09-29 HR HR20090254T patent/HRP20090254T1/xx unknown
- 2006-09-29 DK DK06805947T patent/DK1937221T3/da active
- 2006-09-29 DE DE502006002851T patent/DE502006002851D1/de active Active
- 2006-09-29 PL PL06805947T patent/PL1937221T3/pl unknown
- 2006-09-29 RS RSP-2009/0174A patent/RS50777B/sr unknown
- 2006-09-29 CN CN2006800369452A patent/CN101277683B/zh not_active Expired - Fee Related
- 2006-09-29 WO PCT/EP2006/009466 patent/WO2007042160A1/fr not_active Ceased
- 2006-09-29 SI SI200630266T patent/SI1937221T1/sl unknown
- 2006-09-29 ES ES06805947T patent/ES2322202T3/es active Active
- 2006-09-29 MY MYPI20080752A patent/MY146552A/en unknown
- 2006-09-29 ME MEP-2009-368A patent/ME01735B/fr unknown
- 2006-09-29 AT AT06805947T patent/ATE422354T1/de active
- 2006-09-29 CA CA2624838A patent/CA2624838C/fr not_active Expired - Fee Related
- 2006-09-29 AU AU2006301573A patent/AU2006301573B2/en not_active Ceased
- 2006-09-29 RU RU2008113381/15A patent/RU2419419C2/ru not_active IP Right Cessation
- 2006-09-29 JP JP2008533913A patent/JP2009511441A/ja active Pending
- 2006-09-29 EP EP06805947A patent/EP1937221B1/fr active Active
- 2006-09-29 KR KR1020087008466A patent/KR101362679B1/ko not_active Expired - Fee Related
- 2006-09-29 BR BRPI0617184-2A patent/BRPI0617184A2/pt not_active IP Right Cessation
-
2008
- 2008-03-04 ZA ZA200802031A patent/ZA200802031B/xx unknown
- 2008-03-24 MA MA30779A patent/MA29803B1/fr unknown
- 2008-03-30 IL IL190511A patent/IL190511A/en not_active IP Right Cessation
- 2008-04-04 US US12/062,683 patent/US8231904B2/en not_active Expired - Fee Related
- 2008-04-21 NO NO20081896A patent/NO339360B1/no not_active IP Right Cessation
-
2009
- 2009-04-23 CY CY20091100457T patent/CY1109131T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091064L (no) | Antistoffer mot IL-17A | |
| DE602007010664D1 (de) | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen | |
| WO2012145346A3 (fr) | Compositions nutritionnelles pour améliorer de la performance et procédés pour les préparer et les utiliser | |
| JO2796B1 (en) | Antiallergic drugs IL-8 | |
| CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
| WO2008138943A3 (fr) | Utilisation prophylactique et thérapeutique d'inhibiteurs de la sirtuine dans des pathologies à médiation par tnf-alpha | |
| DOP2010000075A (es) | Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo | |
| IL190511A0 (en) | Retard formulation for pralnacasan | |
| TH85752B (th) | อิฐบล็อก | |
| ATE481965T1 (de) | Feste zusammensetzung mit einer tonerde wie etwa kaolin | |
| TH22298S1 (th) | อิฐบล็อก | |
| TH22301S1 (th) | อิฐบล็อก | |
| TH22295S1 (th) | อิฐบล็อก | |
| TH22303S1 (th) | อิฐบล็อก | |
| TH22292S1 (th) | อิฐบล็อก | |
| TH84848B (th) | อิฐบล็อก | |
| TH22302S1 (th) | อิฐบล็อก | |
| TH84823B (th) | อิฐบล็อก | |
| TH78106S (th) | อิฐบล็อก | |
| TH78092S (th) | อิฐบล็อก | |
| TH81127S (th) | อิฐบล็อก | |
| TH22299S1 (th) | อิฐบล็อก | |
| TH22293S1 (th) | อิฐบล็อก | |
| TH22297S1 (th) | อิฐบล็อก | |
| TH79542S (th) | อิฐบล็อก |